 |
| 삼성바이오로직스. (사진=삼성바이오로직스). |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics is using its group capabilities to accelerate the acquisition of ADC (antibody-drug conjugate· antibody-drug junction) technology capabilities.
Samsung C&T and Samsung BioLogics announced on the 12th that they invested in Araris Biotech AG through the Samsung Life Science Fund (Samsung Life Science Fund). In July 2021, Samsung created a fund worth 150 billion won with the aim of finding new business opportunities in the bio sector.
Araris has a linker technology that plays a key role in the development of ADC medicines.
Through this investment, Samsung plans to cooperate with Araris in the production and development of ADC therapeutics. It also plans to strengthen its ADC capabilities and further expand its related portfolio.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
